The top 20 pharmaceutical companies have implemented a raft of new initiatives in the last two years. Yet in two important areas, progress remains static.

› Go to Key Findings

The industry pipeline is concentrated on five diseases. Five companies are developing more than half the products for developing countries.

› Go to Key Findings

Half of the companies in the Index are developing medicines tailored for children, with 7% of the overall research pipeline being devoted to “child-size” medicine.

› Go to Key Findings

More companies are tailoring their prices to different segments of national populations.

› Go to Key Findings

Home

Analysis Highlights

Download the report

Download the report

2014 Index Ranking

Latest News

Inside the 2014 Access to Medicine Index investor meetings

20 December 2014 |

The 2014 Access to Medicine Index was published on 17 November, 2014.

› Read more

Licensing medicines for HIV/AIDS: critical mechanism for ending the epidemic

1 December 2014 |

For World Aids Day, the Access to Medicine Index has analysed the licensing practices of the top 20 research-based pharmaceutical companies to assess how they are contributing to global efforts to combat HIV/AIDS.

› Read more

2014 Access to Medicine Index – More being done, but progress is uneven

17 November 2014 |

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years.

› Read more

2014 Access to Medicine Index – to be published November 17

15 October 2014 |

"We have the clearest ever picture of how the pharmaceutical industry is performing, and a deeper understanding of what it takes to be a leader,” Wim Leereveld, Index CEO and Founder.

› Read more

Investor meetings – 2014 Index in London, Paris, Basel, NYC

15 October 2014 |

Following publication, the 2014 Access to Medicine Index will be presented to investors and other stakeholders at a series of meetings in Europe and the US. The meetings will provide an opportunity for selected investors, pharmaceutical anal

› Read more

What Leaders Say

Dr. Margaret Chan
Director-General, World Health Organization
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Bill Gates
Chairman of Microsoft Corporation, Co-Chair and Trustee of the Bill & Melinda Gates Foundation
"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Justine Greening
Justine Greening
Secretary of State for International Development, The Rt Hon Justine Greening MP
This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries.
Lilianne Ploumen
Minister for Foreign Trade and Development Cooperation, the Netherlands
“The Access to Medicine Index mobilizes the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment.”
Knut Kjaer
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM) (1997-2007)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

In the Media

The New York Times covers the leaders, risers and fallers in the 2014 Index

2 December 2014 |

Donald McNeil reports GSK's No.1 postition, also noting that more than half of the companies in the 2014 Index are developing paediatric formulations of important drugs.

› Read more

Wall Street Journal uses 2014 Index findings to balance debate

18 November 2014 |

Ed Silverman covers the findings of the 2014 Index, providing nuance in the debate about the role of pharmaceutical companies. He reports that many drug makers are, by and large, making headway for access to medicine.

› Read more

NOS reports that pharma companies are active on behalf of 3rd world – 2014 Index

18 November 2014 |

Dutch public broadcaster, the NOS, publishes the 2014 ranking while reporting on the positive efforts being made by pharmaceutical companies to increase access to medicine in the 3rd world, in its coverage of the 2014 Index. 

› Read more

BMJ reports that progress is being made, but struggles remain – 2014 Index

18 November 2014 |

The British Medical Journal reports that the finding that top drug companies are making drugs more accessible but are also struggling to perform in the area of corruption.

› Read more

FT focuses on GSK's leadership in coverage of 2014 Index

17 November 2014 |

Andrew Ward reports on the drivers behind changes in the Access to Medicine Index, quoting Wim Leereveld and focusing on the reasons behind GSK's No.1 position. 

› Read more